GLP-1 medication vs a diet program compared: average weight loss in STEP, SURMOUNT, Look AHEAD and commercial program trials, side effects, dated monthly costs and what happens after stopping. Not ranked.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- In STEP 1 and SURMOUNT-1, semaglutide 2.4 mg and tirzepatide led to 14.9% and 15.0-20.9% average weight loss, vs 2.4% and 3.1% with placebo plus lifestyle counseling.[4]
- With the same intensive behavioral program for everyone (STEP 3), weight fell 16.0% with semaglutide and 5.7% with the program alone at 68 weeks.[5]
- Commercial programs averaged modest extra losses at 12 months, such as at least 2.6% for WW and 4.9% for Jenny Craig vs education alone.[9]
- After weight-loss medicines stop, weight returned about 0.3 kg a month faster than after behavioral programs end.[14]
- Wegovy and Zepbound are FDA approved for use together with a reduced-calorie diet and increased physical activity.[2]
In short: In their main trials, the weekly GLP-1 medicines Wegovy and Zepbound led to average weight loss of about 15% to 21% over 68 to 72 weeks, while structured diet programs usually average about 3% to 9% in the first year. The medicines cost far more each month, have more side effects and need a prescription, and weight tends to come back faster after they stop. They also aren’t either-or: the FDA approves these medicines for use together with a reduced-calorie diet and more physical activity, and the trials gave everyone a lifestyle program.
This page sets the two approaches side by side using randomized trials, the FDA labels and dated prices, so you can see the trade-offs clearly. It doesn’t pick a winner, because the right path depends on your health, your goals and your budget. For background on the medicines, see our guide to GLP-1 medications; for non-prescription options, see weight-loss programs; for what each path costs, see our cost hub; and for life after either one, see keeping weight off. This is general education, not medical advice. Whether a medicine is right for you is a decision for you and your clinician.
The two approaches in one table
| GLP-1 medication (Wegovy, Zepbound) | Diet or lifestyle program | |
|---|---|---|
| What it is | A weekly injection (or, for Wegovy, a daily pill) that lowers appetite, used with diet and activity changes | A structured plan for eating and activity, often with coaching, group sessions, an app or meals |
| Who it is for | Prescription only; generally considered for adults with a BMI of 30 or more, or 27 or more with a weight-related condition | Open to most adults; some programs (like the National Diabetes Prevention Program) have entry criteria |
| Average weight loss in trials | About 15% (semaglutide) to 21% (tirzepatide, top dose) over 68-72 weeks | About 3% to 9% at one year, depending on intensity |
| Side effects | Common nausea, diarrhea and other stomach effects; boxed warning and serious but less common risks | Few medical risks for most people |
| Monthly cost without insurance | About $149 to $449 at maker self-pay prices (checked 2026-10-07); some Zepbound doses cost up to $699 without on-time refills | About $0 to $70 for most app and group programs (checked 2026-10-07); meal-based programs cost more |
| After stopping | Weight tends to return within about 1 to 2 years on average | Weight also tends to return, but more slowly on average |
The BMI framing comes from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Use our BMI calculator to see your number, keeping in mind that BMI is only one part of what a clinician looks at.
How much weight people lost in the trials
No large trial has assigned people to “a GLP-1 medicine only” versus “a diet program only”. What we have are separate trials of each, and one important detail: in every medicine trial below, the placebo group also got diet and activity counseling. So the placebo numbers show what a basic lifestyle program did in those same studies.
Over a year, the gap adds up. At $349 a month, 12 months of Wegovy pens is $4,188 at the self-pay price, before any doctor visits, while a year of WW Core at $12 a month is $144 and the annual Noom Weight plan is $209. With insurance, a medicine can cost much less: both makers offer savings cards that bring the price to as little as $25 a month when commercial insurance covers the drug, and our guides to GLP-1 coverage, Wegovy cost and Zepbound cost explain the details. Many programs now sell both together: WW’s Med+ membership, for example, is $25 for the first month and then $74 a month on a 12-month plan, with the medicine’s cost not included. Our comparison of telehealth weight-loss programs shows what those bundles include.
What happens after you stop
Obesity is a long-term condition, and both paths face weight regain when they end. The trials show it is faster after a medicine stops. In STEP 1’s extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In the STEP 4 and SURMOUNT-4 withdrawal trials, people who switched to placebo regained 6.9% and 14.0% of their body weight, while those who stayed on the medicine kept losing or held steady.
A 2026 review in the BMJ pooled 37 studies and found that after weight-loss medicines stop, weight comes back at about 0.4 kg (just under 1 lb) a month on average, and blood pressure, cholesterol and blood sugar markers were projected to return to their starting levels within about 1.4 years. Regain after behavioral programs was slower. The authors suggested caution about short-term use of these medicines without a more complete weight-management plan. That is one reason the labels describe the medicines as treatment “long term”, and why people plan the exit with their clinician. Our guide to life after a GLP-1 covers what helps.
Trade-offs people weigh
Here are the honest trade-offs, without a recommendation. Many people end up using both, in different seasons of life.
- How much weight loss matters for your health. For some conditions, a 5% to 10% loss already helps; for others, clinicians aim higher. The medicines reach larger losses more often.
- Side effects you can live with. Nausea and other stomach effects are common on GLP-1s, especially early. Programs carry few medical risks.
- Cost and coverage. Without insurance, a year of medicine costs thousands of dollars; most programs cost a few hundred or less, and Medicare covers its diabetes prevention program for people who qualify.
- How long you plan to stay on it. Weight tends to return faster after a medicine stops, so people often think about the long run before starting.
- Other conditions. Wegovy is also approved to lower heart risk in adults with heart disease, and Zepbound to treat moderate to severe sleep apnea in adults with obesity. Prediabetes has the strongest lifestyle evidence (the DPP).
- Medicines you already take, pregnancy plans and health history. These affect whether a GLP-1 is an option at all, which only your clinician can judge.
A sensible way to decide
- Know your starting pointCheck your BMI and waist, and bring recent labs to a visit.
- Start the habits either wayProtein at meals, more vegetables, regular walks and two strength sessions a week help on both paths.
- Ask about the medicine routeDiscuss whether a GLP-1 fits your health, the side effects and the cost with your clinician.
- Check coverageLook up Wegovy and Zepbound on your plan and ask about prior authorization.
- Plan for the long termAgree on how you will keep weight off if you stop, pause or switch.
If you’re still exploring, our Find My Options tool walks through the main paths, and every way to lose weight, compared puts these two next to surgery, procedures and more. For the medicines themselves, see Wegovy, Zepbound and every FDA-approved weight-loss medication compared. Our printable questions to ask before starting a GLP-1 and how to choose a weight-loss program can help you prepare.
Related guides
GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…
Weight-Loss Programs: commercial, telehealth and clinical comparedWeight-loss programs compared: commercial, app, meal-delivery, telehealth and clinical programs, what to check before signing up,…
Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…
Alternate-Day Fasting vs 16:8 vs 5:2: Fasting Methods ComparedTypes of intermittent fasting compared: 16:8, 5:2 and alternate-day fasting, what a week looks like on…Tools for this topic
BMI Calculator for Adults (and what BMI cannot tell you)Free BMI calculator for adults with CDC categories, plus what BMI cannot tell you, why waist…
Weight-Loss Timeline Calculator: a conservative goal-date estimateFree weight loss calculator: a conservative goal-date range that accounts for your body needing less energy…Latest research
The 10,000 Steps Myth: How Many Steps You Really NeedWhere the 10,000 steps goal came from and what the big studies found: most of the…
How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…
What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…Questions to ask a professional
- Based on my health, how much weight loss would make a real difference for me?
- Am I a candidate for a GLP-1 medicine, and which conditions or medicines might rule one out?
- What side effects should I expect, and how do we handle them?
- Does my insurance cover Wegovy or Zepbound, or a lifestyle program like the Diabetes Prevention Program?
- If I start a medicine, what is the plan if I need to stop?
Frequently asked questions
Is a GLP-1 better than dieting?
Neither is better for everyone. In trials, GLP-1 medicines led to larger average weight loss than diet programs, but they cost more, cause more side effects and need a prescription, and weight tends to come back faster after stopping. The FDA approves them for use with diet and activity changes, not instead of them.
Do I still need to diet on Ozempic, Wegovy or Zepbound?
The labels for Wegovy and Zepbound say they are used in combination with a reduced-calorie diet and increased physical activity, and everyone in the main trials received lifestyle counseling. Eating enough protein and doing strength training also help protect muscle while losing weight.
How much weight do people lose on a diet program?
Usually about 3% to 9% in the first year, depending on how intensive the program is and how many sessions people attend. Look AHEAD averaged 8.6% at one year; the National Diabetes Prevention Program averaged 4.2% in real-world use.
Will I regain weight after stopping a GLP-1?
On average, yes. In the STEP 1 extension, people regained about two-thirds of the weight they lost within a year of stopping semaglutide, and a 2026 BMJ review found regain was faster after medicines than after behavioral programs. Plans for the long term are worth discussing with your clinician before starting.
Which costs less, a GLP-1 or a diet program?
A diet program, in most cases. As checked on 2026-10-07, maker self-pay prices for Wegovy and Zepbound were about $149 to $449 a month, while WW Core started at $12 a month and Noom Weight ranged from $209 a year to $70 a month. Insurance can change the medicine cost a lot.
References
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi:10.1056/NEJMoa2206038 · PMID 35658024 · NCT04184622 (accessed October 7, 2026) Randomized trial
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 2021. doi:10.1001/jama.2021.1831 · PMID 33625476 · NCT03611582 (accessed October 7, 2026) Randomized trial
- Look AHEAD Research Group; Wing RR, et al.. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes (Look AHEAD). New England Journal of Medicine, 2013. doi:10.1056/NEJMoa1212914 · PMID 23796131 · NCT00017953 (accessed October 7, 2026) Randomized trial
- Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine, 2002. doi:10.1056/NEJMoa012512 · PMID 11832527 (accessed October 7, 2026) Randomized trial
- Ely EK, Gruss SM, Luman ET, et al.. A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care, 2017. doi:10.2337/dc16-2099 · PMID 28500215 (accessed October 7, 2026) Other
- Gudzune KA, Doshi RS, Mehta AK, et al.. Efficacy of commercial weight-loss programs: an updated systematic review. Annals of Internal Medicine, 2015. doi:10.7326/M14-2238 · PMID 25844997 (accessed October 7, 2026) Meta-analysis
- Jebb SA, Ahern AL, Olson AD, et al.. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. The Lancet, 2011. doi:10.1016/S0140-6736(11)61344-5 · PMID 21906798 (accessed October 7, 2026) Randomized trial
- Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. doi:10.1111/dom.14725 · PMID 35441470 (accessed October 7, 2026) Randomized trial
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
- Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. doi:10.1001/jama.2023.24945 · PMID 38078870 · NCT04660643 (accessed October 7, 2026) Randomized trial
- West S, Scragg J, Aveyard P, et al.. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 2026. doi:10.1136/bmj-2025-085304 · PMID 41500720 (accessed October 7, 2026) Meta-analysis
- Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 7, 2026) Government page
- Medicare Diabetes Prevention Program. Medicare.gov (CMS). (accessed October 7, 2026) Government page
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Zepbound at LillyDirect: self-pay prices. Eli Lilly and Company. (accessed October 7, 2026) Other
- The Points Program. WW International, Inc.. (accessed October 7, 2026) Other
- How much does Noom Weight cost in 2026?. Noom, Inc., 2026. (accessed October 7, 2026) Other
Facts checked on October 7, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.